Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT03585062 Recruiting - Pancreatic Cancer Clinical Trials

Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer

Start date: November 20, 2017
Phase: Phase 2
Study type: Interventional

The study is to evaluate the R0 resection rate of patients with unresectable locally advanced pancreatic cancer ,after treated with S-1 plus Paclitaxel-albumin as neoadjuvant chemotherapy protocols

NCT ID: NCT03579836 Recruiting - Clinical trials for Metastatic Pancreatic Cancer

Assessment of Safety and Efficacy of BEY1107 in Monotherapy and Combination With Gemcitabine in Patient With Pancreatic Cancer

Start date: May 9, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.

NCT ID: NCT03576872 Not yet recruiting - Clinical trials for Gastro Intestinal Cancer

The GI Binder: A Psychoeducational Intervention for Pancreatic Cancer Patients

Start date: July 31, 2018
Phase: N/A
Study type: Interventional

This research study is evaluating the use of a binder of educational materials with nurse teaching to prepare patients for chemotherapy

NCT ID: NCT03576131 Recruiting - Colorectal Cancer Clinical Trials

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

Start date: May 7, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors

NCT ID: NCT03572400 Not yet recruiting - Pancreatic Cancer Clinical Trials

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

Start date: July 2018
Phase: Phase 2
Study type: Interventional

<Research Hypothesis> The dynamics of immune cells by CCRT/Durvalumab will be uncovered. The combination of Durvalumab with concurrent chemoradiotherapy (CCRT/gemcitabine)) as neoaduvant treatment in resectable or borderline resectable pancreatic cancer is feasible and efficacious. The combination of Durvalumab with cytotoxic chemotherapy (gemcitabine) as an adjuvant treatment is feasible and efficacious. <Objectives> To assess the effect of Neoadjuvant CCRT with Gemcitabine/Durvalumab followed by adjuvant Gemcitabine/Durvalumab in resectable or borderline resectable pancreatic cancer Primary endpoint: 2 year-DFSR (disease-free survival rate) Secondary endpoints - Efficacy: 2 year-OSR (overall survival rate), disease-free survival, overall survival, overall response rate (RECIST 1.1, ir response) after neoadjuvant CCRT, disease control rateEORTC QLQ-C30, the number of immune cells (TIL, macrophage, etc) in resected pancreatic tissue - Safety: toxicity (CTCAE V), irAE, Exploratory Objective(s): - To evaluate baseline measures and changes of immune systems and regulations by neoadjuvant CCRT with gemcitabine/Durvalumab in peripheral blood and tumor tissues - To collect and store DNA from blood (according to ethical procedures) for future exploratory research into genes/genetic variation that may influence response (ie, distribution, safety, tolerability and efficacy) to study treatments and or susceptibility to disease (optional).

NCT ID: NCT03572283 Recruiting - Pancreas Cancer Clinical Trials

Bethanechol Prior to Pancreatic Surgery

Start date: April 8, 2018
Phase: Early Phase 1
Study type: Interventional

The primary objective of this study is to assess the impact of bethanechol therapy on tumor activity by looking at biomarkers of proliferation, macrophage activation, and stem cell markers in post-treatment specimens compared to pre-treatment specimens and compared to other patients who were not treated with bethanechol prior to surgery. The investigators hypothesize that treatment with bethanechol will alter nerve conduction within tumors by stimulating the parasympathetic nervous system and reduce tumor proliferation, reduce macrophage activation and decrease human cluster of differentiation 44 (CD44) protein cancer stem cells. The safety objective is to assess the safety and tolerability of short course bethanechol prior to surgery and the impact of this treatment on immediate surgical outcomes. The investigators will assess all treatment-related toxicities with an emphasis on GI side effects and evaluate the impact of therapy on surgical delays or immediate post-op complications. All subjects will be contacted 1 week after beginning therapy to assess toxicity including GI specific toxicity and followed for safety for 30 days following completion of study medication. The investigators hypothesize that treatment for a minimum of 2 weeks will be tolerable in this selected patient population and will not interfere with progression to surgery or lead to increased surgical complications.

NCT ID: NCT03570502 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

Incidence of POPF in the Resection of the Left Pancreas With RFAT

RFATPancreas
Start date: November 2016
Phase:
Study type: Observational [Patient Registry]

This study evaluates the impact of the Radiofrequency assisted transection on the rate of postoperative pancreatic fistula (POPF) after performing distal pancreatectomies, central pancreatectomies and pancreatic enucleation

NCT ID: NCT03568630 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 2

Blood Markers of Early Pancreas Cancer

Start date: July 1, 2018
Phase:
Study type: Observational

Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.

NCT ID: NCT03567863 Not yet recruiting - Clinical trials for Pancreatic Adenocarcinoma

Study Comparing Pancreatic EUS-FNB With the 20-gauge Procore® and the 22-gauge Acquire® Needles

HISTOPAN
Start date: June 24, 2018
Phase: N/A
Study type: Interventional

Multicenter randomized prospective study Criteria for inclusion: Patients admitted for EUS-FNB of a pancreatic mass Goals of the study: To compare the results of blinded punctures for suspicion of pancreatic tumor performed under endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific. Main criterion: - Biopsy core length of target tissue obtained by needle pass Number of patients: 60 patients Duration of the study: 1 year

NCT ID: NCT03566056 Recruiting - Pancreas Cancer Clinical Trials

Early Recovery Outcomes After Standardized Fast-track Whipples Procedure

Start date: January 18, 2018
Phase:
Study type: Observational [Patient Registry]

Today the Whipple procedure is the preferred operation for malignancy in the pancreas. In abdominal surgery this procedure is known for its high surgical stress-response in the patient, which has been attempted to be resolved with the introduction of preoperative high-dose steroids and goal-directed fluid therapy (GDT). Despite this effort, complications still occur regularly (30%) in the first weeks after the operation here at Rigshospitalet. Therefore there is still a challenge in the patients who have undergone the Whipple procedure in the acute postoperative phase. This shows in for example at Rigshospitalet, where 50% of the patients continue to be in the need of vasoactive medication the morning after the operation. Nevertheless, no studies have in detail described the acute (<24h) postoperative phase. There is also an importance in the fact that there is often no description or control over other important factors, for example medicine with influence on the circulatory system, fluid treatment and response to this etc.. The purpose of this study is to investigate what issues or complications, in particular those of circulatory matter that occurs in this particular group of patients 24 hours after the operation. Furthermore there is lacking a description of which cause-response- link there can be between early and later (30 days) complications, as well as when each of these complications occur. Therefore, there will also be collected data on complications within the first 30 days after the operation for the purpose of a later secondary publication with the same authors.